Robert N Bowser

US Patent:

7572596, Aug 11, 2009

Filed:

Dec 2, 2005

Appl. No.:

11/294161

Inventors:

Robert P. Bowser - Cranberry Township PA, US

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

G01N 33/53
G01N 33/535
G01N 33/72

US Classification:

435 71, 435 79, 435 791, 435 792, 436173, 436174, 436501

Abstract:

The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method for treating ALS in a subject that comprises administering to the subject a transthyretin protein, 7B2 protein, a cystatin C protein, a neuroendocrine protein, a cysteine protease inhibitor, or an inhibitor of an enzyme that processes a 7B2 protein. In addition, the invention provides methods for determining the susceptibility of a subject to developing ALS and for determining the progression of ALS in a subject.

US Patent:

7858071, Dec 28, 2010

Filed:

Oct 25, 2004

Appl. No.:

10/972732

Inventors:

Robert P. Bowser - Cranberry Township PA, US
Srikanth Ranganathan - Pittsburgh PA, US

Assignee:

University of Pittsburgh—Of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 49/00
C40B 30/10
G01N 33/00
G01N 33/48

US Classification:

424 91, 435 795, 702 19, 506 6

Abstract:

The invention provides a method for diagnosing amyotrophic lateral sclerosis (ALS) in a subject, a method for assessing the effectiveness of a drug in treating ALS, and a method for determining the site of onset of ALS in a subject. Each method comprises (a) obtaining a sample from the subject, (b) analyzing the proteins in the sample by mass spectroscopy, and (c) determining a mass spectral profile for the sample. In some embodiments, the method comprises comparing the mass spectral profile of the sample to the mass spectral profile of a positive or a negative standard.

US Patent:

8202510, Jun 19, 2012

Filed:

Dec 1, 2010

Appl. No.:

12/957686

Inventors:

Robert P. Bowser - Cranberry Township PA, US
Srikanth Ranganathan - Germantown MD, US

Assignee:

University of Pittsburgh—Of The Commonwealth System Of Higher Education - Pittsburgh PA

International Classification:

A61K 49/00
G01N 33/00
G01N 33/48
G01N 33/566
C40B 20/08

US Classification:

424 91, 435 795, 702 19, 702 22, 506 6, 436 86, 436 94, 436173, 436501

Abstract:

The invention provides a method for diagnosing amyotrophic lateral sclerosis (ALS) in a subject, a method for assessing the effectiveness of a drug in treating ALS, and a method for determining the site of onset of ALS in a subject. Each method comprises (a) obtaining a sample from the subject, (b) analyzing the proteins in the sample by mass spectroscopy, and (c) determining a mass spectral profile for the sample. In some embodiments, the method comprises comparing the mass spectral profile of the sample to the mass spectral profile of a positive or a negative standard.

US Patent:

8465727, Jun 18, 2013

Filed:

Oct 6, 2010

Appl. No.:

12/899235

Inventors:

Robert P. Bowser - Cranberry Township PA, US

Assignee:

University of Pittsburgh—Of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61B 5/145
G01N 33/48
G01N 33/49
A61K 35/30
A61P 25/02
A61P 25/28

US Classification:

424 91, 435 4, 435 71, 435 792, 702 19, 702 22, 702 23, 514 177, 514 182

Abstract:

Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein (CRP), cystatin c, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH). The sample is typically cerebral spinal fluid (CSF). The levels or concentrations of the biomarkers can be used to determine the onset of ALS, monitor the progression of ALS, or monitor the progression of a treatment for ALS.

US Patent:

20060121619, Jun 8, 2006

Filed:

Dec 2, 2005

Appl. No.:

11/294326

Inventors:

Robert Bowser - Cranberry Township PA, US

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

G01N 33/00

US Classification:

436086000

Abstract:

The invention provides a method for determining the onset and/or progression of ALS in an animal. The method comprises (a) obtaining a sample from the animal, (b) analyzing the proteins in the sample by mass spectroscopy, and (c) determining a mass spectral profile for the sample. The invention also provides isolated protein biomarkers of ALS.

US Patent:

20090104639, Apr 23, 2009

Filed:

Sep 12, 2008

Appl. No.:

12/209899

Inventors:

Robert P. Bowser - Cranberry Township PA, US

Assignee:

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

C12Q 1/37
G01N 33/53
C12Q 1/02

US Classification:

435 23, 436 86, 435 29

Abstract:

The invention provides methods of determining a diagnosis or prognosis of motor neuron disease in a mammal comprising determining the expression level of one or more proteins or polypeptides of the renin-angiotensin system in a sample taken from a subject. Similarly, aberrant post-translational modification of the proteins or polypeptides as compared to a negative control indicates a diagnosis of disease.

US Patent:

20100292149, Nov 18, 2010

Filed:

Jul 24, 2009

Appl. No.:

12/508908

Inventors:

Robert P. Bowser - Cranberry Township PA, US

International Classification:

A61K 38/11
A61K 38/17
A61K 31/7105
A61P 25/28
A61K 38/31
G01N 33/53
G01N 33/00

US Classification:

514 109, 514 135, 514 44 R, 514 177, 514 181, 514 111, 435 792, 436 86, 436 94

Abstract:

The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method for treating ALS in a subject that comprises administering to the subject a transthyretin protein, 7B2 protein, a cystatin C protein, a neuroendocrine protein, a cysteine protease inhibitor, or an inhibitor of an enzyme that processes a 7B2 protein. In addition, the invention provides methods for determining the susceptibility of a subject to developing ALS and for determining the progression of ALS in a subject.

US Patent:

20130280733, Oct 24, 2013

Filed:

Jun 17, 2013

Appl. No.:

13/919432

Inventors:

Robert P. Bowser - Cranberry Township PA, US

International Classification:

G01N 33/68

US Classification:

435 79

Abstract:

Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein (CRP), cystatin c, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH). The sample is typically cerebral spinal fluid (CSF). The levels or concentrations of the biomarkers can be used to determine the onset of ALS, monitor the progression of ALS, or monitor the progression of a treatment for ALS.